Literature DB >> 9260122

Epidemiological pitfalls using Medicaid data in reproductive health research.

J A Grisso1, J L Carson, H I Feldman, I Cosmatos, M Shaw, B Strom.   

Abstract

The purpose of this report is to discuss methodologic issues in using Medicaid claims data to conduct epidemiologic analyses in reproductive health. We conducted case-control studies that used Medicaid claims data to evaluate two specific reproductive health questions. Case and control pregnancies were selected from among 106,000 women identified in a Medicaid claims file. Medical record review was conducted for randomly selected cases and controls. Several methodological issues were identified. Women could contribute multiple pregnancies that qualified as either case pregnancies, control pregnancies, or both. The results of the medical record review indicated that 25% of one case group (low-birthweight infants) could not be confirmed, and 70% of the second case group (CNS birth defects) were misclassified. Thirty-five percent of women classified as not having undergone diagnostic ultrasonography based on Medicaid claims data had evidence of having received diagnostic ultrasound during pregnancy on the basis of medical record review. Several problems were encountered with the use of Medicaid billing data to address epidemiologic questions in reproductive health. Although solutions to some of these problems could be identified, others could not be addressed without careful review of the medical records. These limitations may not apply to all state Medicaid databases or other claims data, but they should be carefully considered when planning claims-based analyses of reproductive health issues.

Entities:  

Mesh:

Year:  1997        PMID: 9260122     DOI: 10.1002/(SICI)1520-6661(199707/08)6:4<230::AID-MFM9>3.0.CO;2-K

Source DB:  PubMed          Journal:  J Matern Fetal Med        ISSN: 1057-0802


  8 in total

1.  Using Medicaid data to estimate state- and county-level prevalence of asthma among low-income children.

Authors:  P A Buescher; K Jones-Vessey
Journal:  Matern Child Health J       Date:  1999-12

2.  How do we best detect toxic effects of drugs taken during pregnancy? A EuroMap paper.

Authors:  Jørn Olsen; Andrew Czeizel; Henrik Toft Sørensen; Gunnar Lauge Nielsen; Lolkje T W de Jong van den Berg; Lorentz M Irgens; Charlotte Olesen; Lars Pedersen; Helle Larsen; Rolv T Lie; Corinne S de Vries; Ulf Bergman
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  Children who are medically fragile in North Carolina: using Medicaid data to estimate prevalence and medical care costs in 2004.

Authors:  Paul A Buescher; J Timothy Whitmire; Susan Brunssen; Catherine E Kluttz-Hile
Journal:  Matern Child Health J       Date:  2006-06-03

4.  Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance.

Authors:  Sarah C MacDonald; Jacqueline M Cohen; Alice Panchaud; Thomas F McElrath; Krista F Huybrechts; Sonia Hernández-Díaz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-07-22       Impact factor: 2.890

5.  Reliability of medicaid claims versus medical record data: in a cost analysis of palivizumab.

Authors:  Julie Jacobson Vann; John Feaganes; Steven Wegner
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

6.  Issues and biases in matching medicaid pregnancy episodes to vital records data: the Arkansas experience.

Authors:  Janet M Bronstein; Charles T Lomatsch; David Fletcher; Terri Wooten; Tsai Mei Lin; Richard Nugent; Curtis L Lowery
Journal:  Matern Child Health J       Date:  2008-05-01

7.  Evaluating Medicaid HMOs when encounter data are missing: case of developmentally delayed children.

Authors:  Farrokh Alemi; P J Maddox; Valentin Prudius; Victoria Doyon
Journal:  Health Care Manag Sci       Date:  2003-02

8.  Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations.

Authors:  Kristin Palmsten; Krista F Huybrechts; Helen Mogun; Mary K Kowal; Paige L Williams; Karin B Michels; Soko Setoguchi; Sonia Hernández-Díaz
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.